Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEWMEDS

Financiado

Cerrado

Novel Methods leading to New Medications in Depression and Schizophrenia

Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major bottle-necks”: a lack of eti... ver más

28/02/2015

H. LUNDBECK AS

25M€

Presupuesto del proyecto: 25M€

Líder del proyecto

H. LUNDBECK AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2015-02-28 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

H. LUNDBECK AS

Lider

CSIC

N.D. | Participante

Pfizer RD UK Limited

N.D. | Participante

ABBV

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NEWMEDS Novel Methods leading to New Medications in Depression and S... 25M€ Cerrado

EU-AIMS European Autism Interventions A Multicentre Study for Deve... 37M€ Cerrado

EU-AIMS European Autism Interventions - A Multicentre Study for Deve... 37M€ Cerrado

RxMine A simple blood test to choose the best treatment for each pa... 4M€ Cerrado

IDENTIFICACIÓN DE NUEVAS ASOCIACIONES GENOTIP... IDENTIFICACIÓN DE NUEVAS ASOCIACIONES GENOTIPO FENOTIPO EN R... 2M€ Cerrado

TACtIK Trace Amine Associated Receptor 1 TAAR1 agonists in a chem... 213K€ Cerrado

Duración del proyecto: 65 meses Fecha Inicio: 2009-09-01
Fecha Fin: 2015-02-28

Líder del proyecto

H. LUNDBECK AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 25M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical trials on DSM categories which provide a collection of biologically heterogeneous patients. Our broad working hypothesis is that a focus on cross-species endophenotypes, testing in healthy volunteers and finding biologically-homogenous groups of patients will overcome existing limitations in target identification, early triage and clinical trials. To implement this idea six leading European institutions and two SMEs will partner with the EFPIA to: a) develop animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g., cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of fMRI-based endopheno types in genetically-selected healthy volunteers and patients as early and surrogate markers for efficacy; and to combine this with PET approaches for plasma-kinetics to brain-dynamics modelling to provide guidance regarding optimal clinical trial design; and c) identify pharmacogenetic and multi-omic biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for ) targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms; Bayesian analyses) and willactively collaborate with other ongoing international efforts (esp. the Biomarkers Consortium, NIH).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores